CD8A and neoplasm: Collectively, these data demonstrate that vvDD-IL-23 treatment elicited potent systemic antitumor effects in late-stage tumor models and the antitumor effect is IFN-γ- CD8+ T cell- and CD4+ T cell-dependent.